Background and Aims: Nintedanib represents an antifibrotic compound able to slow down disease progression of patients with idiopathic pulmonary fibrosis (IPF).
(23 males, median age: 74.5, mean%FVC AE SD = 71.1 AE 20.1 .
The most frequent adverse event was liver dysfunction with a rate of 34.4%. Nineteen patients (59.4%) experienced adverse event. In this study, patients were able to manage diarrhoea with anti-diarrheal. Although all adverse events were improved in a short period of time after discontinue administration of medication, 11 patients (34.4%) had to permanently discontinue nintedanib due to severe adverse events.
Conclusion:
The most common adverse event was liver dysfunction followed by nausea and diarrhoea, which was different from a previous studies. 
Results:
ILD-LC group preponderates in male ratio, age and smoking indices than ILD group (P < 0.05).
ILD-LC group preponderates in CA19-9, CA125, CYFRA21-1, CEA than ILD group (P < 0.05).
In ILD-LC group, tumours were mainly generated within interstitial lesion region, mainly presented as peripheral carcinoma and typically characterized by adenocarcinoma from vitreous lesions and multiple pulmonary metastasis lesions.
LC group preponderates in mutation ration of EGFR than ILD-LC group (P < 0.05).
Conclusion: High-risk factors for pathogenesis of ILD-LC include aging, smoking, male preponderance. Expression of tumor markers generally goes in parallel with pathogenesis of tumor. Most lesions are presented as peripheral carcinoma pathologically defined as adenocarcinoma, with limited mutation ratio of EGFR. Methods: A case of a 49-year old female, Asian, no co-morbidities presented with progressive dyspnea. On physical examination, respiratory system showed asymmetric lung expansion, tachypnea, decreased vocal and tactile fremitus in the right base. Hyperresonant on the right base.
Decreased breath sounds on the right mid to base lung field. Other systems were unremarkable. Chest radiograph showed pneumothorax on the right and HRCT done showing diffusely varisized thin walled cystic lesions with intervening normal lung. Cranial MRI was unremarkable and abdominal ultrasound showed minimal ascitis. She was subjected for video assisted thoracotomy with biopsy which showed HMB45 and SMA positive, definitive of LAM.
Results: LAM is a rare disease of unknown ethology. Definite diagnosis is characterized by HRCT findings suggestive of LAM and immunostaining positive for HMB45 and SMA. There is no specific treatment for this condition. However, more recently sirolimus have been implied in the management of LAM. Surgical intervention is needed for the management of recurrent pneumothorax. Our patient presented with progressive dyspnea with no other features of tuberous sclerosis. She was diagnosed with definite LAM based on the HRCT findings plus the Immunostaining results.
Conclusion: LAM is a rare disease characterized by the proliferation of unique smooth muscle -like cell involving the small airways, pulmonary microvasculature, and lymphatic structures causing an airway obstruction, cystic changes in the lung parenchyma and pneumothorax. Background and Aims: Hyaluronan (HA), a non-sulfated glycosaminoglycan is a major constituent of the extracellular matrix (ECM), and growing evidence shows its important roles on inflammation, injury and repair in the lung. We have previously demonstrated that serum HA was significantly higher in patients with clinically stable idiopathic interstitial pneumonia (IIP) than healthy controls, and had a positive correlation with CRP and SP-D. In addition, HA was positively correlated with the percentage of inflammatory cells and CXCL8 in bronchoalveolar lavage (BAL) fluid. These results indicate that HA is involved in the pathogenesis of several pulmonary diseases. However, the clinical significance of HA in autoimmune pulmonary alveolar proteinosis (aPAP) has not been clarified. The goal of this study was to determine whether HA is a clinically useful biomarker in patients with aPAP.
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